Weekly Analysts’ Ratings Changes for Rocket Pharmaceuticals (RCKT)

A number of firms have modified their ratings and price targets on shares of Rocket Pharmaceuticals (NASDAQ: RCKT) recently:

• 5/16/2025 – Rocket Pharmaceuticals had its price target raised by analysts at Cantor Fitzgerald from $20.00 to $30.00. They now have an “overweight” rating on the stock.
• 5/16/2025 – Rocket Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $32.00 price target on the stock.
• 5/16/2025 – Rocket Pharmaceuticals had its price target raised by analysts at Chardan Capital from $45.00 to $46.00. They now have a “buy” rating on the stock.
• 5/12/2025 – Rocket Pharmaceuticals had its price target lowered by analysts at Scotiabank from $52.00 to $51.00. They now have a “sector outperform” rating on the stock.
• 5/12/2025 – Rocket Pharmaceuticals had its price target lowered by analysts at Canaccord Genuity Group Inc. from $36.00 to $34.00. They now have a “buy” rating on the stock.
• 5/9/2025 – Rocket Pharmaceuticals had its price target lowered by analysts at JPMorgan Chase & Co. from $45.00 to $44.00. They now have an “overweight” rating on the stock.
• 5/9/2025 – Rocket Pharmaceuticals had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $15.00 to $13.00. They now have a “neutral” rating on the stock.
• 5/9/2025 – Rocket Pharmaceuticals had its price target lowered by analysts at Chardan Capital from $54.00 to $45.00. They now have a “buy” rating on the stock.
• 4/9/2025 – Rocket Pharmaceuticals had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $42.00 price target on the stock.

Rocket Pharmaceuticals Stock Performance

RCKT traded up $0.40 on Tuesday, hitting $6.85. 2,465,459 shares of the stock traded hands, compared to its average volume of 1,490,378. The business has a fifty day moving average price of $6.89 and a two-hundred day moving average price of $10.16. The company has a current ratio of 6.05, a quick ratio of 6.05 and a debt-to-equity ratio of 0.06. Rocket Pharmaceuticals, Inc. has a 52 week low of $4.55 and a 52 week high of $26.98. The firm has a market capitalization of $731.48 million, a PE ratio of -2.49 and a beta of 1.02.

Rocket Pharmaceuticals (NASDAQ:RCKT) last issued its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.56) EPS for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.02. During the same period last year, the business earned ($0.66) earnings per share. On average, research analysts predict that Rocket Pharmaceuticals, Inc. will post -2.83 EPS for the current fiscal year.

Insider Transactions at Rocket Pharmaceuticals

In other Rocket Pharmaceuticals news, insider Kinnari Patel purchased 21,099 shares of the business’s stock in a transaction on Wednesday, April 9th. The stock was purchased at an average price of $4.70 per share, for a total transaction of $99,165.30. Following the completion of the purchase, the insider now directly owns 26,774 shares in the company, valued at approximately $125,837.80. This trade represents a 371.79% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Gaurav Shah bought 20,000 shares of the company’s stock in a transaction dated Thursday, April 10th. The stock was bought at an average cost of $5.08 per share, with a total value of $101,600.00. Following the completion of the acquisition, the chief executive officer now owns 792,680 shares in the company, valued at $4,026,814.40. This represents a 2.59% increase in their position. The disclosure for this purchase can be found here. 24.76% of the stock is owned by insiders.

Institutional Investors Weigh In On Rocket Pharmaceuticals

Large investors have recently made changes to their positions in the company. Wellington Management Group LLP boosted its position in Rocket Pharmaceuticals by 24.5% in the fourth quarter. Wellington Management Group LLP now owns 13,995,177 shares of the biotechnology company’s stock valued at $175,919,000 after buying an additional 2,753,033 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Rocket Pharmaceuticals by 0.6% in the first quarter. Vanguard Group Inc. now owns 6,617,784 shares of the biotechnology company’s stock valued at $44,141,000 after buying an additional 40,189 shares in the last quarter. Westfield Capital Management Co. LP increased its stake in shares of Rocket Pharmaceuticals by 2.3% in the first quarter. Westfield Capital Management Co. LP now owns 4,820,701 shares of the biotechnology company’s stock valued at $32,154,000 after buying an additional 106,091 shares in the last quarter. Janus Henderson Group PLC raised its holdings in shares of Rocket Pharmaceuticals by 111.0% in the fourth quarter. Janus Henderson Group PLC now owns 4,004,039 shares of the biotechnology company’s stock valued at $50,343,000 after buying an additional 2,106,699 shares during the last quarter. Finally, Suvretta Capital Management LLC acquired a new position in Rocket Pharmaceuticals during the 4th quarter worth about $32,267,000. Institutional investors own 98.39% of the company’s stock.

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.